Lupin has informed that it enclosed is a press release on 6th September 2021 as regards granting of a non-exclusive license to the Company to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen, by Non-profit drug developer, TB Alliance. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.